晚期癌性贫血患者血清促红细胞生成素和网织红细胞参数的分析

目的研究对晚期癌性贫血患者促红细胞生成素(EPO)的水平及其对患者贫血症状作用的临床意义。方法收集多种晚期癌性贫血患者血清,应用放射免疫法检测EPO水平。以正常人、非癌性贫血患者作为对照。同时检测各组血红蛋白(Hb)、网织红细胞参数包括网织红细胞数(RET)、网织红细胞生成指数(RPI)。分析各组EPO水平差异及其与Hb、网织红细胞参数的相关性。结果晚期癌性贫血组患者血清EPO为(2.69±1.30)μg/L,RET(2.78±1.06)%,RPI1.44±0.32;正常对照组患者血清EPO为(1.59±0.69)μg/L,RET(1.17±0.35)%,RPI0.98±0.25;非癌性贫血组患者血清EPO为(2.78±1.53)μg/L,RET(5.46±2.12)%,RPI2.34±0.35;癌性贫血组患者与正常对照组患者比较,其血清EPO、Hb、RET、RPI值均存在显著差异(P<0.01);癌性贫血组患者与非癌性贫血组患者比较,RET、RPI检测结果存在显著差异(P<0.01);癌性贫血组和非癌性贫血组患者EPO和RET、RPI值的相关系数存在显著差异(P<0.01)。结论晚期癌性贫血患者血清EPO水平反应性增高,但机体对EPO反应性减弱。

Detection and Clinical Analysis of Erythropoitin and Eeticulocyte in Patients with Advanced Cancer-Related Anemia

Objective To etect erythropoitin in patients with advanced cancer-related anemia and analyse the clinical signification.Methods Blood of patients with advanced cancer-related anemia were collected and erythropoitin was detected by radioimmuno-assay,hemoglobin(Hb) and reticulocyte(RET),reticulocyte production index(RPI) were detected also.Normal and patients with non-cancer-related anemia were employed as control groups.Results The erythropoitin of patients with advanced cancer-related anemia was(2.69±1.30) μg/L,hemoglobin(89.8±10.0) g/L,reticulocyte(2.78±1.06)%,RPI 1.44±0.32.Erythropoitin was(1.59±0.69) μg/L,hemoglobin(136.1±11.3) g/L,reticulocyte(1.17±0.35)%,RPI 0.98±0.25 in normal controls.Erythropoitin was(2.82±1.16) μg/L,hemoglobin(90.2±11.5) g/L,reticulocyte(5.7 ±2.7)%,RPI 2.34 ±0.35 in controls of non-cancer-related anemia.Compared with normal controls,the erythropoitin,hemoglobin and reticulocyte,RPI of patients with advanced cancer-related anemia were significant difference(P <0.01).The reticulocyte and RPI were significant different compared the patients with advanced cancer-related anemia with the patients with non-cancer-related anemia(P <0.01).The coefficient of correlation between erythropoitin and reticulocyte,RPI were significant different in the patients with advanced cancer-related anemia compared with the patients with non-cancer-related anemia(P <0.01).Conclusion The erythropoitin of patients with advanced cancer-related anemia increased responsively but the reactivity of erythropoitin decreased.